# Hospital-acquired pneumonia

## Microbiology

Send a sample (sputum sample, nasopharyngeal swab or tracheal aspirate) for processing.

### **Antibiotics**

Start antibiotic treatment as soon as possible after establishing a diagnosis of hospital-acquired pneumonia, and within 4 hours of clinical suspicion if symptoms start in hospital or within 4 hours of presentation to hospital.

When choosing an antibiotic(s), take account of:

- disease severity (based on clinical judgement)
- number of days in hospital before onset of symptoms
- the risk of developing complications, for example if the person has a relevant comorbidity (such as severe lung disease or immunosuppression)
- local hospital and ward-based antimicrobial resistance data
- · recent antibiotic use
- recent microbiological results, including colonisation with multi-drug resistant bacteria
- recent contact with health or social care setting before current admission
- the risk of adverse effects with broad spectrum antibiotics, including Clostridium difficile infection.

Give oral antibiotics first line if the person can take oral medicines, and the severity of their condition does not require intravenous antibiotics.

If intravenous antibiotics are given, review by 48 hours and, if possible, consider switching to oral antibiotics to complete the course.

Stop antibiotics after 5 days unless microbiological results suggest a longer course is needed or the person is not clinically stable.



### **Definitions**

## Hospital-acquired pneumonia:

- develops 48 hours or more after hospital admission, or
- is present at admission in people who have been discharged from hospital within the last 7 to 10 days.


In this guideline, hospital-acquired pneumonia does not include pneumonia developing after intubation (ventilator-associated penumonia).

Higher risk of resistance includes symptoms or signs starting more than 5 days after hospital admission, relevant comorbidity such as severe lung disease or immunosuppression, recent use of broad spectrum antibiotics, colonisation with multi-drug resistant bacteria and recent contact with health or social care setting before current admission.

Follow the recommendations on community-acquired pneumonia if symptoms or signs start within:

- 48 hours of admission
- 3 to 5 days of admission and the person is not at higher risk of resistance.

Reassess people if symptoms or signs do not improve as expected or worsen rapidly or significantly.



# Hospital-acquired pneumonia

| Choice of antibiotic: adults aged 18 years and over   |   |  |
|---|---|--|
| Antibiotic  | Dosage and course length                            |  |
| First-line oral antibiotic for non-severe symptoms or signs and not at higher risk of resistance  |   |  |
| Co-amoxiclav  | 500/125 mg three times a day for 5 days then review |  |
| Alternative oral antibiotics for non-severe symptoms or signs and not at higher risk of resistance, if penicillin allergy or if co-amoxiclav unsuitable. Base choice on specialist microbiological advice and local resistance data. Options include: |   |  |

| Doxycycline   | 200 mg on first day, then 100 mg once a day for 4 days (5-day course) then review                                   |
|---|---|
| Cefalexin (caution in penicillin allergy)   | 500 mg twice or three times a day (can be increased to 1 to 1.5 g three or four times a day) for 5 days then review |
| Co-trimoxazole  | 960 mg twice a day for 5 days then review   |
| Levofloxacin (only if switching from intravenous levofloxacin with specialist advice) | 500 mg once or twice a day for 5 days then review   |

First-line intravenous antibiotics if severe symptoms or signs (for example, of sepsis) or at higher risk of resistance. Base choice on specialist microbiological advice and local resistance data. Options include:

| Piperacillin with tazobactam                                       | 4.5 g three times a day (increased to 4.5 g four times a day if severe infection)                                      |
|--|--|
| Ceftazidime  | 2 g three times a day  |
| Ceftriaxone  | 2 g once a day   |
| Cefuroxime   | 750 mg three times a day (increased to 750 mg four times a day or 1.5 g three or four times a day if severe infection) |
| Meropenem  | 0.5 to 1 g three times a day   |
| Ceftazidime with avibactam   | 2/0.5 g three times a day  |
| Levofloxacin (only if other first-line antibiotics are unsuitable) | 500 mg once or twice a day (use higher dosage if severe infection)   |

| Choice of antibiotic: adults aged 18 years and over, continued  |  |  |
|---|--|--|
| Antibiotic  | Dosage and course length   |  |
| Antibiotics to be added if suspected or confirmed MRSA infection (dual therapy with with a first-line intravenous antibiotic) |  |  |
| Vancomycin  | 15 to 20 mg/kg two or three times a day intravenously, adjusted according to serum vancomycin; loading dose of 25 to 30 mg/kg for serious illness (maximum 2 g per dose) |  |
| Teicoplanin   | Initially 6 mg/kg every 12 hours for 3 doses, then 6 mg/kg once a day  |  |
| Linezolid (if vancomycin cannot be used; specialist advice only)  | 600 mg twice a day orally or intravenously   |  |

#### Notes


For **all antibiotics**: see <u>BNF</u> for appropriate use and dosing in specific populations, for example, hepatic impairment, renal impairment, pregnancy and breast-feeding, and administering intravenous (or, where appropriate, intramuscular) antibiotics. Oral doses are for immediate-release medicines.

For **first-line and alternative choice oral antibiotics:** review treatment after a total of 5 days of antibiotics and consider stopping the antibiotic if clinically stable.

For **co-trimoxazole**: see BNF for information on monitoring of patient parameters and therapeutic drug monitoring. In September 2024, this was an off-label use (see <u>NICE's information on prescribing medicines</u>).


For **vancomycin**, **teicoplanin** and **linezolid**: see BNF for information on monitoring of patient parameters and therapeutic drug monitoring.

(!) Warning: for levofloxacin, see the MHRA January 2024 advice on restrictions and precautions for using fluoroquinolone antibiotics because of the risk of disabling and potentially long-lasting or irreversible side effects. Fluoroquinolones must now only be prescribed when other commonly recommended antibiotics are inappropriate. In september 2024 levofloxacin for hospital-acquired pneumonia was an off-label use. See NICE's information on prescribing medicines



# Hospital-acquired penumonia

| Choice of antibiotic: children and young people under 18 years  |   |  |  |
|---|---|--|--|
| Antibiotic  | Dosage and course length  |  |  |
| Children 1 month and over: first-line oral anti   | Children 1 month and over: first-line oral antibiotic if non-severe symptoms or signs and not at higher risk of resistance  |  |  |
| Co-amoxiclav  | 1 to 11 months, 0.5 ml/kg of 125/31 suspension three times a day for 5 days then review 1 to 5 years, 10 ml of 125/31 suspension three times a day or 0.5 ml/kg of 125/31 suspension three times a day for 5 days then review 6 to 11 years, 10 ml of 250/62 suspension three times a day or 0.3 ml/kg of 250/62 suspension three times a day for 5 days then review 12 to 17 years, 500/125 mg three times a day for 5 days then review (or 5 ml of 250/62 suspension) |  |  |
| Children 1 month and over: alternative oral antibiotic if non-severe symptoms or signs and not at higher risk of resistance, for penicillin allergy or if co-amoxiclav unsuitable. Other options may be suitable based on specialist microbiological advice and local resistance data |   |  |  |
| Clarithromycin  | 1 month to 11 years: under 8 kg, 7.5 mg/kg twice a day for 5 days then review; 8 to 11 kg, 62.5 mg twice a day for 5 days then review; 12 to 19 kg, 125 mg twice a day for 5 days then review; 20 to 29 kg, 187.5 mg twice a day for 5 days then review; 30 to 40 kg, 250 mg twice a day for 5 days then review 12 to 17 years, 500 mg twice a day for 5 days then review   |  |  |
| Children 1 month and over: first-line intravenous antibiotics if severe symptoms or signs (for example, symptoms or signs of sepsis) or at higher risk of resistance. Antibiotic choice based on specialist microbiological advice only and local resistance data. Options include:   |   |  |  |
| Piperacillin with tazobactam  | 1 month to 11 years, 90 mg/kg three or four times a day (maximum 4.5 g per dose four times a day) 12 to 17 years, 4.5 g three times a day (increased to 4.5 g four times a day if severe infection)   |  |  |
| Ceftazidime   | 1 month to 17 years, 25 mg/kg three times a day (50 mg/kg three times a day if severe infection; maximum 6 g per day)   |  |  |
| Ceftriaxone   | 1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (use dose at higher end of range if severe infection; maximum 4 g per day) 9 to 11 years (50 kg and above), 2 g once a day 12 to 17 years, 2 g once a day  |  |  |
| Children 1 month and over: antibiotics to be added if suspected or confirmed MRSA infection (dual therapy with a first-line intravenous antibiotic)   |   |  |  |
| Teicoplanin   | 1 month, initially 16 mg/kg for 1 dose, then 8 mg/kg once daily, subsequent dose given 24 hours after initial dose (doses given by intravenous infusion) 2 months to 11 years, initially 10 mg/kg every 12 hours intravenously for 3 doses, then 6 to 10 mg/kg once daily intravenously 12 to 17 years, initially 6 mg/kg every 12 hours intravenously for 3 doses, then 6 mg/kg once daily intravenously   |  |  |
| Vancomycin  | 1 months to 11 years, 10 to 15 mg/kg four times a day, adjusted according to serum vancomycin 12 to 17 years, 15 to 20 mg/kg two or three times a day, adjusted according to serum vancomycin, loading dose of 25 to 30 mg/kg for serious illness (maximum 2 g per dose)  |  |  |
| Linezolid (if vancomycin cannot be used; specialist advice only)  | 3 months to 11 years, 10 mg/kg three times a day orally or intravenously (maximum 600 mg per dose) 12 to 17 years, 600 mg twice a day orally or intravenously   |  |  |
| Notes   |   |  |  |



See over page.

# Hospital-acquired pneumonia

Choice of antibiotic: children and young people under 18 years, continued

#### **Notes**

For **all antibiotics**: see <u>BNFC</u> for use and dosing in specific populations, for example, hepatic impairment, renal impairment, pregnancy and breast-feeding, and administering intravenous (or, where appropriate, intramuscular) antibiotics. Oral doses are for immediate-release medicines. Prescribers to use age bands with other factors such as severity and child's size in relation to the average for children of the same age.

For first-line and alternative choice oral antibiotics: review treatment after a total of 5 days of antibiotics and consider stopping the antibiotic if clinically stable.

For teicoplanin, vancomycin and linezolid: see BNFC for information on monitoring of patient parameters and on therapeutic drug monitoring.

For linezolid: in September 2024 linezolid for children and young people under 18 years was an off-label use (see NICE's information on prescribing medicines).

